Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant hepatic arterial infusion pump chemotherapy after resection of low-risk colorectal liver metastases
NL-OMON60090Phase 3Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of floxuridine in colorectal cancer (CRC) and colorectal cancer liver metastasis (CRLM) (2 arms), sponsored by Erasmus MC. Primary endpoint: Progression-free survival. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
floxuridine
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on NL-OMON60090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60090.